blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3105593

EP3105593 - ANTIBODY DIRECTED AGAINST GABARAPL1 FOR USE IN THE TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2016/51]METHOD FOR DETERMINING THE LEVEL OF HYPOXIA IN A TUMOR
[2018/18]
StatusThe application is deemed to be withdrawn
Status updated on  25.01.2019
Database last updated on 13.11.2024
FormerGrant of patent is intended
Status updated on  19.04.2018
FormerExamination is in progress
Status updated on  22.09.2017
FormerRequest for examination was made
Status updated on  18.11.2016
Most recent event   Tooltip25.01.2019Application deemed to be withdrawnpublished on 27.02.2019  [2019/09]
Applicant(s)For all designated states
Universiteit Maastricht
Minderbroedersberg 4-6
6211 LK Maastricht / NL
For all designated states
Academisch Ziekenhuis Maastricht
P. Debyelaan 25
6229 HX Maastricht / NL
[2016/51]
Inventor(s)01 / ROUSCHOP, Kasper Mathias Antoon
Universiteitssingel 50
Dept. of radiotherapy, room 3.318
6200 MD Maastricht / NL
02 / KEULERS, Tom Gertrudis Hubertus
Universiteitssingel 50
Dept. of radiotherapy, room 3.318
6200 MD Maastricht / NL
 [2016/51]
Representative(s)Life Science Patents B.V.
Oxfordlaan 55
6229 EV Maastricht / NL
[N/P]
Former [2016/51]Habets, Winand
Life Science Patents
PO Box 5096
6130 PB Sittard / NL
Application number, filing date15703614.611.02.2015
[2016/51]
WO2015EP52854
Priority number, dateEP2014015469811.02.2014         Original published format: EP 14154698
[2016/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015121295
Date:20.08.2015
Language:EN
[2015/33]
Type: A1 Application with search report 
No.:EP3105593
Date:21.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 20.08.2015 takes the place of the publication of the European patent application.
[2016/51]
Search report(s)International search report - published on:EP20.08.2015
ClassificationIPC:A61K39/395, C07K16/28
[2018/18]
CPC:
G01N33/57488 (EP,US); C07K16/18 (EP,US); C07K16/286 (EP,US);
C07K2317/76 (EP,US); G01N2800/7038 (US)
Former IPC [2016/51]G01N33/574, A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/51]
TitleGerman:ANTIKÖRPER GEGEN GABARAPL1 ZUR VERWENDUNG BEI DER BEHANDLUNG VON KREBS[2018/18]
English:ANTIBODY DIRECTED AGAINST GABARAPL1 FOR USE IN THE TREATMENT OF CANCER[2018/18]
French:ANTICORPS ANTI-GABARAPL1 POUR UTILISATION DANS LE TRAITEMENT DU CANCER[2018/18]
Former [2016/51]VERFAHREN ZUR BESTIMMUNG DES HYPOXÄMIEPEGELS IN EINEM TUMOR
Former [2016/51]METHOD FOR DETERMINING THE LEVEL OF HYPOXIA IN A TUMOR
Former [2016/51]PROCÉDÉ DE DÉTERMINATION DE NIVEAU D'HYPOXIE DANS UNE TUMEUR
Entry into regional phase26.07.2016National basic fee paid 
26.07.2016Designation fee(s) paid 
26.07.2016Examination fee paid 
Examination procedure29.07.2016Examination requested  [2016/51]
29.07.2016Date on which the examining division has become responsible
20.03.2017Amendment by applicant (claims and/or description)
22.09.2017Despatch of a communication from the examining division (Time limit: M04)
11.01.2018Reply to a communication from the examining division
20.04.2018Communication of intention to grant the patent
31.08.2018Application deemed to be withdrawn, date of legal effect  [2019/09]
10.10.2018Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2019/09]
Fees paidRenewal fee
27.02.2017Renewal fee patent year 03
27.02.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2011133879  (UNIV MASSACHUSETTS [US], et al) [Y] 6,9,11 *Relevant for assessing unity of invention* * page 2, line 23 - line 28 * * page 9, line 4 - line 12 * * page 9, line 25 - page 10, line 4 * * page 16, line 24 - page 17, line 22 * * page 60, line 1 - line 26 * * page 76, line 27 - page 77, line 7 * * claims 5, 43 *;
 [Y]WO2007051316  (BRITISH COLUMBIA CANCER AGENCY [CA], et al) [Y] 6,9,11 * paragraphs [0006] - [0010] - [0 53] * * claim 8 *;
 [AD]US2003044862  (GIACCIA AMATO J [US], et al) [AD] 1-11 * paragraphs [0003] , [0010] , [0011] , [0032] - [0035] - [0064] , [0067] * * claim 1 *;
 [A]US2014038901  (LYDEN DAVID C [US], et al) [A] 1-11 * the whole document *;
 [A]  - JACLYN NICOLE LE GRAND ET AL, "GABARAPL1 (GEC1): Original or copycat?", AUTOPHAGY, (20111001), vol. 7, no. 10, doi:10.4161/auto.7.10.15904, ISSN 1554-8627, pages 1098 - 1107, XP055181239 [A] 1-11 *Relevant for assessing unity of invention* * page 1103, paragraph "The Role of GABARAPL1 in Cancer" *

DOI:   http://dx.doi.org/10.4161/auto.7.10.15904
 [AD]  - "13th International Wolfsberg Meeting on Molecular Radiation Biology / Oncology 2013 - Program", (20130622), URL: http://www.wolfsberg-meeting.com/sites/default/files/Progr_Wolfsberg Meeting 2013_final.pdf, (20150407), XP055181235 [AD] 1-11 *Relevant for assessing unity of invention* * Poster PIV.16 *
 [AD]  - VALADI H ET AL, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 9, no. 6, doi:10.1038/NCB1596, ISSN 1465-7392, (20070601), pages 654 - 659, (20070507), XP002546815 [AD] 1-11 * abstract *

DOI:   http://dx.doi.org/10.1038/NCB1596
    [ ] - VALADI ET AL, "Supporting information - Table S2", NATURE CELL BIOLOGY, (20070601), vol. 9, no. 6, XP002726744 [ ] * page 2 *
 [A]  - JOANNA BAGINSKA ET AL, "The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity", FRONTIERS IN IMMUNOLOGY, (20130101), vol. 4, doi:10.3389/fimmu.2013.00490, XP055127091 [A] 1-11 * the whole document *

DOI:   http://dx.doi.org/10.3389/fimmu.2013.00490
 [A]  - ZHANG YANQUAN ET AL, "GABARAPL1 Negatively Regulates Wnt/beta-catenin Signaling by Mediating Dvl2 Degradation through the Autophagy Pathway", CELL PHYSIOL BIOCHEM, (20110101), vol. 27, pages 503 - 512, XP055181165 [A] 1-11 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.